UCB's Phase III lupus failure casts further shadow over field
This article was originally published in Scrip
Executive Summary
UCB's leading lupus drug, epratuzumab, has failed to meet primary endpoints in two Phase III trials – an event which could deter future investment from this historically tricky development space.
You may also be interested in...
Inside The Lupus Pipeline: Reasons For Optimism
Several drugs for systemic lupus erythematosus (SLE) and lupus nephritis are in mid-to-late stage development, which could pave the way for new treatments for a disease with few options. Experts say they are energized by the amount of investment in lupus R&D.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.